KC-6096

293T-rhesus-RANKL Cell Line

×
Please enable JavaScript in your browser to complete this form.
62412
Home » 293T-rhesus-RANKL Cell Line

Background of 293T-rhesus-RANKL Cell Line

RANKL (Receptor Activator of NF-κB Ligand), officially named TNFSF11 (TNF Superfamily Member 11), is also known as OPGL, ODF, and TRANCE . It is a key cytokine for osteoclast differentiation, activation, and survival . Expressed in bone, lymphoid tissues, and activated T-cells, it binds to its receptor RANK to regulate bone remodeling . Dysregulation of the RANKL/RANK/OPG axis is central to diseases like postmenopausal osteoporosis, rheumatoid arthritis, and bone metastases . This has made RANKL a critical therapeutic target, leading to the development of the monoclonal antibody Denosumab, which inhibits its activity . Current research explores engineered RANKL fragments as novel osteoporosis therapies .

Specifications

Catalog NumberKC-6096
Cell Line Name293T-rhesus-RANKL Cell Line
NCBI/UniProt Accession NumberF7F5R8
Clone Number8#
Host Cell Line293T
DescriptionStable 293T cell line expressing exogenous rhesus RANKL gene
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM + 20% FBS + 10% DMSO
Propagation MediumDMEM + 10% FBS + 1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial-like
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

293T-rhesus-RANKL cell line was generated using a lentiviral vector expressing the rhesus RANKL sequence.

Characterization

Figure 1: Characterization of rhesus RANKL overexpression in the 293T-rhesus-RANKL stable clone using FACS.

Figure 2: Characterization of rhesus RANKL in the 293T-rhesus-RANKL stable clone using PCR sequencing.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Bae, Seyeon et al. “RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts.” Cellular & molecular immunology vol. 20,1 (2023): 94-109. doi:10.1038/s41423-022-00959-x
2. Ando, Yutaro, and Masayuki Tsukasaki. Nihon yakurigaku zasshi. Folia pharmacologica Japonica vol. 158,3 (2023): 263-268. doi:10.1254/fpj.22122
3. Tobeiha, Mohammad et al. “RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling.” BioMed research international vol. 2020 6910312. 19 Feb. 2020, doi:10.1155/2020/6910312
Please enable JavaScript in your browser to complete this form.